At our annual general meeting on April 28, 2022, Henry Dubina will be nominated as an additional independent director of our Company.
Mr. Dubina has +20 years of experience in chemical technology and was the president and Strategic Business Unit Head of Mettler-Toledo AutoChem from 1999 until his retirement in 2022.
“Telescope Industries” is a new branch of the Company dedicated to resolving process and manufacturing inefficiencies in the chemical industry. For its first project, Telescope Industries has been engaged by Hatch Ltd. (“Hatch”), a global engineering, project management, and professional services firm. Hatch has contracted Telescope to perform a series of physical chemistry studies leveraging Telescope’s unique analytical toolsets.
Telescope’s Annual General Meeting will take place on April 28, 2022.
Access the documentation below:
Telescope has engaged Translational Life Sciences Inc. (“TLS”) to evaluate the potential therapeutic effects of Telescope’s proprietary, psilocybin-like novel chemical entities.
Read the news release…
We have delivered on three milestones to set the foundation for unlocking future value for shareholders:
1. Established a growing intellectual property portfolio on pharmaceutical manufacturing,
2. Increased in-house research capacity and proprietary research platforms, and;
3. Brought in award winning scientific leadership.
This patent filing covers novel synthetic routes for manufacturing psilocybin and psilocin along with their precursors, analogs, and derivatives. The application claims the priority date of a preceding provisional application filed with the United States Patent and Trade Office on December 31, 2020.
Read the news release…
The University of British Columbia has assigned to Telescope all interest in our provisional patent application related to scalable synthetic psilocybin and other tryptamine compounds.
Read the news release…
Thank you for your continued support of Telescope Innovations Corp. as we transition to a publicly listed company on the Canadian Securities Exchange (the “CSE”). Telescope’s common shares were approved to list on the CSE on September 27, 2021 under the ticker symbol TELI.
Telescope’s foundation is its world class chemistry team led by Prof. Jason Hein, a recognized authority in organic process chemistry and automated experimentation. He is continually sought out by the pharmaceutical industry to solve complex chemical problems that require creative new tools. His teams develop, integrate, and apply new technologies such as advanced robotics and analytical techniques to address these previously intractable problems.
Our name reflects our commitment to optimizing process chemistry: telescoping synthesis involves tailoring complex, multi-step processes down into one-pot reactions that are more efficient and scalable. We also specialize in using unique analytical tools to “watch” chemical reactions as they are unfolding, enabling us to see possibilities that are otherwise out of reach.
